Delta-Fly Pharma Inc. (4598)
Market Closed
12 Aug, 06:00
JPX JPX Primary ¥
105. 00
-2
-1.8692%
¥
6.72B Market Cap
- P/E Ratio
- Div Yield
144,400 Volume
- Eps
¥ 107
Previous Close Want to track 4598 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
4598 closed today lower at ¥105, a decrease of -1.8692% from yesterday's close, completing a monthly decrease of -17.3228% or -¥22. Over the past 12 months, 4598 stock lost -79.4118%.
4598 is not paying dividends to its shareholders.
The last earnings report, released on May 14, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Delta-Fly Pharma Inc. (4598) FAQ
What is the stock price today?
The current price is ¥105.00.
On which exchange is it traded?
Delta-Fly Pharma Inc. is listed on JPX.
What is its stock symbol?
The ticker symbol is 4598.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 6.72B.
Has Delta-Fly Pharma Inc. ever had a stock split?
No, there has never been a stock split.
Delta-Fly Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Kiyoshi Eshima Ph.D. CEO | JPX Exchange | JP3549370009 ISIN |
| Japan Country | 13 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Delta-Fly Pharma, Inc., founded in 2010 and with its headquarters located in Tokushima, Japan, is at the forefront of anticancer drug development. The company's dedication to advancing cancer treatment encompasses a wide spectrum of research and development activities focused on bringing innovative therapeutic options to patients suffering from various types of cancer. With a robust pipeline of drugs at different stages of clinical trials in the United States and Japan, Delta-Fly Pharma, Inc. is poised to make significant contributions to oncology therapeutics.
Products and Services
- DFP-10917: Currently in a phase III clinical trial in the United States and a phase I trial in Japan, DFP-10917 is designed to treat relapsed/refractory acute myeloid leukemia (AML), aiming to offer hope to patients who have limited treatment options.
- DFP-14323: This is another promising drug in Delta-Fly Pharma's pipeline, undergoing a phase III clinical trial specifically for lung cancer treatment. Its progression into advanced clinical trials underscores the company's commitment to tackling one of the most common and lethal cancers worldwide.
- DFP-17729: Engaged in phase I/II clinical trials, DFP-17729 targets solid cancers with an innovative approach. As it progresses through the phases, it represents the company's extensive efforts in expanding its oncology portfolio to include treatments for a broad range of cancers.
- DFP-11207: Having completed phase I clinical trial, DFP-11207 focuses on pancreatic cancer, a notoriously challenging disease with a high demand for more effective treatment options. Its development reflects Delta-Fly Pharma's dedication to addressing hard-to-treat cancers.
- DFP-14927: Currently in phase I, this drug is aimed at treating hematologic cancers, demonstrating the company's ongoing commitment to discovering new therapies for various types of blood cancer.
- DFP-10825: Still in the preclinical trial phase, DFP-10825 offers potential for treating gastric and ovarian cancers. As it moves towards clinical trials, it symbolizes the early but critical steps in battling these significant cancer types.
Contact Information
Address: 37-5 Nishikino
Phone: -
Website: https://www.delta-flypharma.co.jp
